211 related articles for article (PubMed ID: 27482610)
1. EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HIPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALS.
O'Neil PM; Garvey WT; Gonzalez-Campoy JM; Mora P; Ortiz RV; Guerrero G; Claudius B; Pi-Sunyer X;
Endocr Pract; 2016 Nov; 22(11):1277-1287. PubMed ID: 27482610
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials.
Ard J; Cannon A; Lewis CE; Lofton H; Vang Skjøth T; Stevenin B; Pi-Sunyer X
Diabetes Obes Metab; 2016 Apr; 18(4):430-5. PubMed ID: 26744025
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
O'Neil PM; Birkenfeld AL; McGowan B; Mosenzon O; Pedersen SD; Wharton S; Carson CG; Jepsen CH; Kabisch M; Wilding JPH
Lancet; 2018 Aug; 392(10148):637-649. PubMed ID: 30122305
[TBL] [Abstract][Full Text] [Related]
4. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
le Roux CW; Astrup A; Fujioka K; Greenway F; Lau DCW; Van Gaal L; Ortiz RV; Wilding JPH; Skjøth TV; Manning LS; Pi-Sunyer X;
Lancet; 2017 Apr; 389(10077):1399-1409. PubMed ID: 28237263
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial.
Garvey WT; Birkenfeld AL; Dicker D; Mingrone G; Pedersen SD; Satylganova A; Skovgaard D; Sugimoto D; Jensen C; Mosenzon O
Diabetes Care; 2020 May; 43(5):1085-1093. PubMed ID: 32139381
[TBL] [Abstract][Full Text] [Related]
6. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
Rubino DM; Greenway FL; Khalid U; O'Neil PM; Rosenstock J; Sørrig R; Wadden TA; Wizert A; Garvey WT;
JAMA; 2022 Jan; 327(2):138-150. PubMed ID: 35015037
[TBL] [Abstract][Full Text] [Related]
7. Exposure-response analyses of liraglutide 3.0 mg for weight management.
Wilding JP; Overgaard RV; Jacobsen LV; Jensen CB; le Roux CW
Diabetes Obes Metab; 2016 May; 18(5):491-9. PubMed ID: 26833744
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m²: A Post-hoc Analysis.
le Roux C; Aroda V; Hemmingsson J; Cancino AP; Christensen R; Pi-Sunyer X
Obes Facts; 2017; 10(6):531-544. PubMed ID: 29145215
[TBL] [Abstract][Full Text] [Related]
9. Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.
Larsen JR; Vedtofte L; Jakobsen MSL; Jespersen HR; Jakobsen MI; Svensson CK; Koyuncu K; Schjerning O; Oturai PS; Kjaer A; Nielsen J; Holst JJ; Ekstrøm CT; Correll CU; Vilsbøll T; Fink-Jensen A
JAMA Psychiatry; 2017 Jul; 74(7):719-728. PubMed ID: 28601891
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
Davies MJ; Bergenstal R; Bode B; Kushner RF; Lewin A; Skjøth TV; Andreasen AH; Jensen CB; DeFronzo RA;
JAMA; 2015 Aug; 314(7):687-99. PubMed ID: 26284720
[TBL] [Abstract][Full Text] [Related]
11. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials.
O'Neil PM; Aroda VR; Astrup A; Kushner R; Lau DCW; Wadden TA; Brett J; Cancino AP; Wilding JPH;
Diabetes Obes Metab; 2017 Nov; 19(11):1529-1536. PubMed ID: 28386912
[TBL] [Abstract][Full Text] [Related]
12. Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial.
Neeland IJ; Marso SP; Ayers CR; Lewis B; Oslica R; Francis W; Rodder S; Pandey A; Joshi PH
Lancet Diabetes Endocrinol; 2021 Sep; 9(9):595-605. PubMed ID: 34358471
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 analogue, in Latino/Hispanic patients with type 2 diabetes: post hoc analysis of data from four phase III trials.
Davidson JA; Ørsted DD; Campos C
Diabetes Obes Metab; 2016 Jul; 18(7):725-8. PubMed ID: 26936426
[TBL] [Abstract][Full Text] [Related]
14. Liraglutide: A Glucagon-Like Peptide-1 Agonist for Chronic Weight Management.
Manigault KR; Thurston MM
Consult Pharm; 2016 Dec; 31(12):685-697. PubMed ID: 28074747
[TBL] [Abstract][Full Text] [Related]
15. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial.
Blackman A; Foster GD; Zammit G; Rosenberg R; Aronne L; Wadden T; Claudius B; Jensen CB; Mignot E
Int J Obes (Lond); 2016 Aug; 40(8):1310-9. PubMed ID: 27005405
[TBL] [Abstract][Full Text] [Related]
16. Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects.
Bays H; Pi-Sunyer X; Hemmingsson JU; Claudius B; Jensen CB; Van Gaal L
Curr Med Res Opin; 2017 Feb; 33(2):225-229. PubMed ID: 27817208
[TBL] [Abstract][Full Text] [Related]
17. One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients.
Svensson CK; Larsen JR; Vedtofte L; Jakobsen MSL; Jespersen HR; Jakobsen MI; Koyuncu K; Schjerning O; Nielsen J; Ekstrøm CT; Correll CU; Vilsbøll T; Fink-Jensen A
Acta Psychiatr Scand; 2019 Jan; 139(1):26-36. PubMed ID: 30374965
[TBL] [Abstract][Full Text] [Related]
18. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Pi-Sunyer X; Astrup A; Fujioka K; Greenway F; Halpern A; Krempf M; Lau DC; le Roux CW; Violante Ortiz R; Jensen CB; Wilding JP;
N Engl J Med; 2015 Jul; 373(1):11-22. PubMed ID: 26132939
[TBL] [Abstract][Full Text] [Related]
19. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial.
Halawi H; Khemani D; Eckert D; O'Neill J; Kadouh H; Grothe K; Clark MM; Burton DD; Vella A; Acosta A; Zinsmeister AR; Camilleri M
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):890-899. PubMed ID: 28958851
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
